_2020091018165303jzv.jpg "Decoding The World Of ETF")
-
My Account
My Account
BSE Live
Feb 26, 14:28Prev. Close
1865.50
Open Price
1874.95
Bid Price (Qty.)
1848.10 (6)
Offer Price (Qty.)
1852.80 (21)
NSE Live
Feb 26, 14:28Prev. Close
1866.80
Open Price
1851.20
Bid Price (Qty.)
1848.95 (7)
Offer Price (Qty.)
1851.95 (21)
| Half Yearly Results of Ipca Laboratories (in Rs. Cr.) | Mar '20 | Sep '19 | Mar '19 | Sep '18 | Mar '18 | |
| Net Sales/Income from operations | 2,143.86 | 2,223.57 | 1,781.40 | 1,851.75 | 1,641.96 | |
| Other Operating Income | -- | -- | -- | -- | -- | |
| Total Income From Operations | 2,143.86 | 2,223.57 | 1,781.40 | 1,851.75 | 1,641.96 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 721.69 | 709.41 | 560.32 | 537.70 | 450.87 | |
| Purchase of Traded Goods | 104.83 | 99.82 | 84.84 | 83.03 | 96.53 | |
| Increase/Decrease in Stocks | -118.05 | -37.00 | -76.48 | -29.66 | 2.44 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 445.60 | 425.19 | 353.07 | 399.17 | 350.91 | |
| Depreciation | 91.54 | 87.15 | 84.23 | 87.65 | 86.97 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 531.63 | 569.55 | 453.28 | 574.71 | 470.12 | |
| P/L Before Other | 366.62 | 369.45 | 322.14 | 199.15 | 184.12 | |
| Other Income | 30.93 | 33.76 | 27.21 | 27.38 | 22.36 | |
| P/L Before Int. | 397.55 | 403.21 | 349.35 | 226.53 | 206.48 | |
| Interest | 7.27 | 8.52 | 11.18 | 7.31 | 12.05 | |
| P/L Before Exceptional Items & Tax | 390.28 | 394.69 | 338.17 | 219.22 | 194.43 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 390.28 | 394.69 | 338.17 | 219.22 | 194.43 | |
| Tax | 65.89 | 66.62 | 68.52 | 33.96 | 37.54 | |
| P/L After Tax from Ordinary Activities | 324.39 | 328.07 | 269.65 | 185.26 | 156.89 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 324.39 | 328.07 | 269.65 | 185.26 | 156.89 | |
| Equity Share Capital | 25.27 | 25.27 | 25.27 | 25.27 | 25.24 | |
| Reserves Excluding Revaluation Reserves | -- | 3,389.63 | -- | 2,847.82 | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 25.67 | 25.96 | -- | 14.66 | -- | |
| Diluted EPS | -- | 25.96 | -- | 14.66 | -- | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 25.67 | 25.96 | -- | 14.66 | -- | |
| Diluted EPS. | -- | 25.96 | -- | 14.66 | -- | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
05.02.2021
Ipca Labs Consolidated December 2020 Net Sales at Rs 1,409.83 crore, up 16.24% Y-o-Y
05.02.2021
Ipca Labs Standalone December 2020 Net Sales at Rs 1,315.22 crore, up 15.46% Y-o-Y
04.02.2021
Ipca Laboratories Q3 net profit rises 35% to Rs 267.56 crore
04.02.2021
Ipca Labs Consolidated December 2020 Net Sales at Rs 1,409.83 crore, up 16.24% Y-o-Y
